An observational study in Cataract, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.
Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Cataract by Second Affiliated Hospital, School of Medicine, Zhejiang University — 6 open to participants now, 6 under way, none of them phase 3. Cataract · Second Affiliated Hospital, School of Medicine, Zhejiang University.
Among the 11 studies in Cataract by Second Affiliated Hospital, School of Medicine, Zhejiang University, this one is the only one that started in 2026, is one of 2 observational ones, and was the 11th registered.
1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.
Browse Cataract studies →6 of the 11 studies in Cataract by Second Affiliated Hospital, School of Medicine, Zhejiang University are open now, in 1 country. Recruiting first, the newest first:
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 40–80
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 40+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–80
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–80
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 50–80
By country, each count listing its studies:
Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 200 is above the median of 90 across 477 observational studies indexed under Cataract.
Median enrollment 100 across the 9 interventional studies, 130 across the 2 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Second Affiliated Hospital, School of Medicine, Zhejiang University is the lead sponsor of 1,042 studies on the registry; 499 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Cataract by Second Affiliated Hospital, School of Medicine, Zhejiang University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to evaluate the expression characteristics and clinical relevance of the tRF-31/HIPK2 signaling axis in adults over 18 years old with age-related cataract (ARC). The main questions it aims to answer are: Is there a correlation between the relative expression levels of tRF-31 and its target gene HIPK2 in the anterior lens capsule and the clinical severity (Emery-Little grading system) of age-related cataracts? Does oxidative stress in the anterior segment microenvironment have a potential bystander effect on the state of the corneal endothelium? Participants will:Undergo routine preoperative ophthalmologic examinations, including visual acuity tests, slit-lamp photography, and corneal endothelial cell counting. Undergo standard cataract surgery (phacoemulsification combined with intraocular lens implantation) as part of their regular medical care. Allow researchers to collect and analyze their anterior lens capsule tissue, which is routinely removed and typically discarded as medical waste during the standard continuous curvilinear capsulorhexis (CCC) step of the surgery.
The study population consists of adult patients over 18 years of age who have been clinically diagnosed with age-related cataract (ARC) and are scheduled to undergo routine phacoemulsification combined with intraocular lens implantation at the Eye Center of the Second Affiliated Hospital, Zhejiang University School of Medicine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients older than 18 years. Clinically diagnosed with age-related cataract (ARC) and have clear surgical indications for routine phacoemulsification combined with intraocular lens (IOL) implantation. Scheduled to undergo cataract extraction and intraocular lens implantation. Completed routine preoperative corneal endothelial specular microscopy, providing objective data including cell density, coefficient of variation of cell area, and the proportion of hexagonal cells. Provided signed written .
Exclusion Criteria:
History of ocular trauma, glaucoma, episodes of active uveitis, or previous intraocular surgery. Presence of severe systemic diseases rendering the patient unsuitable for surgery. Poor patient compliance or coexisting psychiatric disorders. Severe systemic metabolic syndromes (e.g., diabetes). Diagnosis of high myopia. Current participation in other clinical trials or likelihood of being lost to follow-up.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is an observational study without investigational interventions. Participants will undergo standard-of-care phacoemulsification combined with intraocular lens implantation for age-related cataract. During the routine continuous curvilinear capsulorhexis (CCC) step of the surgery, the central anterior lens capsule, which is typically discarded as medical waste, will be collected for subsequent molecular analysis. This tissue collection relies entirely on the standard surgical procedure and does not alter the patient's routine clinical treatment pathway in any way.
Correlation between relative expression of tRF-31 and cataract nuclear hardness (Emery-Little grading system)
Time frame: Baseline (Preoperative, up to 1 month prior to surgery)
Started Jun 2026 (actual). Primary completion is estimated for Aug 2026, 1 month after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Second Affiliated Hospital, School of Medicine, Zhejiang University →